| 000 | nam a22 7a 4500 | ||
|---|---|---|---|
| 999 |
_c71288 _d71288 |
||
| 003 | FUTML | ||
| 005 | 20230515122417.0 | ||
| 007 | TA | ||
| 008 | 230511b2021 nyua|||gr|||| 001 0 eng d | ||
| 020 | _a9780815347774 | ||
| 037 | _aB-45560 | ||
| 040 |
_aFUTML _bENGLISH _cFUTML |
||
| 050 |
_aRM301.4 _bB43 2021. |
||
| 100 |
_aBEHERA, B.K. _934655 |
||
| 245 |
_aBIOPHARMACEUTICALS CHALLENGES AND OPPORTUNITIES _cBY BASANTA K BEHERA.- |
||
| 260 |
_aNEW YORK: _bCRC Press, _cc2021 . |
||
| 300 |
_axv,278p.: _bill, _c29cm |
||
| 504 | _aIndex | ||
| 590 | _aB-45560/Magdalene/11/05/2023 | ||
| 650 |
_aPharmaceutical biotechnology _933182 |
||
| 650 |
_aBiopharmaceutics _934656 |
||
| 912 |
_aMagdalene _bMagdalene _cAustine |
||
| 942 |
_2lcc _cBKS |
||
| 949 |
_aIBB GK _cRM301.4 _dB43 2021 _g2342144102 _nNC1 |
||